Clinical Trial

Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study will evaluate safety and clinical benefit of AIGIV used for treatment of patients with systemic anthrax. The study is designed to collect information on safety, clinical benefit (such as extent of anthrax illness and survival) and serum concentrations of AIGIV (for AIGIV pharmacokinetics) and anthrax toxins from sporadic cases of systemic anthrax patients treated with AIGIV.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2018-06-15; most recent amendment 2026-02-04.
Trial Details
NCT Number NCT03569514
Lead Sponsor Emergent BioSolutions
Collaborators: Centers for Disease Control and Prevention, Department of Health and Human Services
Conditions Anthrax
Enrollment 10 participants
Start Date 2026-11-30
Primary Completion 2027-07 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-02-06